{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:18:22Z","timestamp":1778717902064,"version":"3.51.4"},"reference-count":44,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Neonatal seizures are associated with neurological sequelae and an increased risk of epilepsy later in life. Phenobarbital and phenytoin remain the antiepileptic drugs (AEDs) most commonly used to treat neonatal seizures, despite their suboptimal effectiveness and safety. As a result, other AEDs, such as levetiracetam and topiramate, are often used in neonates with refractory seizures, despite limited data and off-label use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>To systematically review published pharmacokinetic data for second-line AEDs used in neonates with seizures and to provide dosing recommendations for these agents in the neonatal population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>A literature search was conducted in PubMed (1949-May 2012), Medline (1950-May 2012), and Embase (1980-May 2012). Each study was ranked according to the quality of evidence it provided, based on the classification system developed by the US Preventive Services Task Force. Information extracted from each study included study design, number of subjects, gestational and postnatal age, AED dosage regimen, pharmacokinetic parameters, pharmacokinetic model, AED serum concentrations, and sampling times.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Nineteen relevant pharmacokinetic studies involving a total of 8 different drugs were identified. No prospective, randomized, controlled studies (level I evidence) or nonrandomized controlled studies (level II-I evidence) were identified; 2 studies were prospective, nonrandomized, uncontrolled (cohort) studies (level II-2 evidence), 11 studies obtained evidence from multiple time series (level II-3 evidence), and 6 studies were case reports or descriptive studies (level III evidence).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>There are limited pharmacokinetic data for the use of carbamazepine, levetiracetam, lidocaine, paraldehyde, topiramate, valproic acid, and vigabatrin for neonates with seizures refractory to treatment with first-line antiepileptic agents. Further research is needed to elucidate target AED serum concentrations (if any) required to optimize effectiveness and minimize dose-related adverse effects in neonates.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-17.1.31","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T19:48:11Z","timestamp":1603828091000},"page":"31-44","source":"Crossref","is-referenced-by-count":9,"title":["A Systematic Review of the Pharmacokinetics of Antiepileptic Drugs in Neonates With Refractory Seizures"],"prefix":"10.5863","volume":"17","author":[{"given":"Joanie K","family":"Tulloch","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxane R","family":"Carr","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary H.H","family":"Ensom","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"19","key":"2020102715455368100_i1551-6776-17-1-31-b01","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1212\/01.wnl.0000279335.85797.2c","article-title":"Long-term prognosis in children with neonatal seizures: a population-based study","volume":"69","author":"Ronen","year":"2007;","journal-title":"Neurology"},{"issue":"2","key":"2020102715455368100_i1551-6776-17-1-31-b02","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.21167","article-title":"Neonatal seizures","volume":"62","author":"Silverstein","year":"2007;","journal-title":"Ann Neurol"},{"issue":"5","key":"2020102715455368100_i1551-6776-17-1-31-b03","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/0883073808327832","article-title":"Controversies in neonatal seizure management","volume":"24","author":"Glass","year":"2009;","journal-title":"J Child Neurol"},{"issue":"6","key":"2020102715455368100_i1551-6776-17-1-31-b04","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.pediatrneurol.2008.03.003","article-title":"Neonatal seizures: dilemmas in workup and management","volume":"38","author":"Bassan","year":"2008;","journal-title":"Pediatr Neurol"},{"issue":"7","key":"2020102715455368100_i1551-6776-17-1-31-b05","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199908123410704","article-title":"Phenobarbital compared with phenytoin for the treatment of neonatal seizures","volume":"341","author":"Painter","year":"1999;","journal-title":"N Engl J Med"},{"issue":"7","key":"2020102715455368100_i1551-6776-17-1-31-b06","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s004310100760","article-title":"Carbamazepine in phenobarbital-nonresponders: experience with ten preterm infants","volume":"160","author":"Hoppen","year":"2001;","journal-title":"Eur J Pediatr"},{"issue":"2","key":"2020102715455368100_i1551-6776-17-1-31-b07","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2008.04.008","article-title":"Off-label use of antiepileptic drugs for the treatment of neonatal seizures","volume":"39","author":"Silverstein","year":"2008;","journal-title":"Pediatr Neurol"},{"issue":"4","key":"2020102715455368100_i1551-6776-17-1-31-b08","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199529040-00005","article-title":"Clinical pharmacokinetics of antiepileptic drugs in paediatric patients: part 1: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide","volume":"29","author":"Battino","year":"1995;","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2020102715455368100_i1551-6776-17-1-31-b09","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00003088-199529050-00004","article-title":"Clinical pharmacokinetics of antiepileptic drugs in paediatric patients: part 2: phenytoin, carbamazepine, sulthiame, Lamotrigine, vigabatrin, oxcarbazepine and felbamate","volume":"29","author":"Battino","year":"1995;","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2020102715455368100_i1551-6776-17-1-31-b10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200645040-00002","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age","volume":"45","author":"Perucca","year":"2006;","journal-title":"Clin Pharmacokinet"},{"key":"2020102715455368100_i1551-6776-17-1-31-b11","unstructured":"US Preventative Services Task Force. Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force. 2nd ed. Baltimore (MD): Williams & Wilkins;1996."},{"issue":"suppl 3","key":"2020102715455368100_i1551-6776-17-1-31-b12","first-page":"17","article-title":"Carbamazepine efficacy and utilization in children","volume":"28","author":"Dobson","year":"1987;","journal-title":"Epilepsia"},{"issue":"1","key":"2020102715455368100_i1551-6776-17-1-31-b13","first-page":"345","article-title":"Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults","volume":"51","author":"Reith","year":"2001;","journal-title":"J Pharmacokineti Biopharm"},{"issue":"5","key":"2020102715455368100_i1551-6776-17-1-31-b14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/088307389601100506","article-title":"Treatment of neonatal seizures with carbamazepine","volume":"11","author":"Singh","year":"1996;","journal-title":"J Child Neurol"},{"issue":"2","key":"2020102715455368100_i1551-6776-17-1-31-b15","first-page":"90","article-title":"Pharmacokinetics of carbamazepine in the neonate and in the child","volume":"17","author":"Rey","year":"1979;","journal-title":"Int J Clin Pharmacol Biopharm"},{"issue":"2","key":"2020102715455368100_i1551-6776-17-1-31-b16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000457734","article-title":"Is carbamazepine an alternative maintenance therapy for neonatal seizures?","volume":"10","author":"MacKintosh","year":"1987;","journal-title":"Dev Pharmacol Ther"},{"issue":"4","key":"2020102715455368100_i1551-6776-17-1-31-b17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1528-1157.1985.tb05657.x","article-title":"Free and total serum concentrations of carbamazepine and carbamazepine 10,11-epoxide in infancy and childhood","volume":"26","author":"Rivia","year":"1985;","journal-title":"Epilepsia"},{"issue":"12","key":"2020102715455368100_i1551-6776-17-1-31-b18","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology-drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003;","journal-title":"N Engl J Med"},{"issue":"7","key":"2020102715455368100_i1551-6776-17-1-31-b19","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008;","journal-title":"Epilepsia"},{"issue":"1","key":"2020102715455368100_i1551-6776-17-1-31-b20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jpeds.2011.03.057","article-title":"Pharmacokinetics of levetiracetam in neonates with seizures","volume":"159","author":"Merhar","year":"2011","journal-title":"J Pediatr"},{"issue":"7-8","key":"2020102715455368100_i1551-6776-17-1-31-b21","first-page":"675","article-title":"Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography tandem mass spectrometry","volume":"878","author":"Blonk","year":"2010;","journal-title":"J Chromatog"},{"issue":"1","key":"2020102715455368100_i1551-6776-17-1-31-b22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/0883073807299973","article-title":"Levetiracetam for the treatment of neonatal seizures","volume":"22","author":"Shoemaker","year":"2007;","journal-title":"J Child Neurol"},{"issue":"4","key":"2020102715455368100_i1551-6776-17-1-31-b23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00148581-200810040-00003","article-title":"Use of second-generation antiepileptic drugs in the pediatric population","volume":"10","author":"Chung","year":"2008;","journal-title":"Paediatr Drugs"},{"issue":"3","key":"2020102715455368100_i1551-6776-17-1-31-b24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1017\/S0012162206000466","article-title":"Intravenous lidocaine for status epilepticus during childhood","volume":"48","author":"Hamano","year":"2006;","journal-title":"Dev Med Child Neurol"},{"issue":"(1);","key":"2020102715455368100_i1551-6776-17-1-31-b25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1651-2227.1992.tb12075.x","article-title":"Lidocaine for treatment of severe seizures in newborn infants. II. Blood concentrations of lidocaine and metabolites during intravenous infusion","volume":"81","author":"Hellstrom-Westas","year":"1992;","journal-title":"Acta Paediatr"},{"issue":"4","key":"2020102715455368100_i1551-6776-17-1-31-b26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00007691-199007000-00003","article-title":"Intravenous lidocaine in the treatment of convulsions in the neonatal period: monitoring plasma levels","volume":"12","author":"Rey","year":"1990;","journal-title":"Ther Drug Monit"},{"issue":"9","key":"2020102715455368100_i1551-6776-17-1-31-b27","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00431-006-0136-x","article-title":"Development of an optimal lidocaine infusion strategy for neonatal seizures","volume":"165","author":"Malingre","year":"2006;","journal-title":"Eur J Pediatr"},{"issue":"25","key":"2020102715455368100_i1551-6776-17-1-31-b28","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJM197412192912504","article-title":"Lidocaine in the prevention of of primary ventricular fibrillation: a double blind randomized study of 212 consecutive patients","volume":"291","author":"Lie","year":"1974;","journal-title":"N Engl J Med"},{"issue":"7","key":"2020102715455368100_i1551-6776-17-1-31-b29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/11589160-000000000-00000","article-title":"Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures","volume":"50","author":"Van den Broek","year":"2011;","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2020102715455368100_i1551-6776-17-1-31-b30","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/BF00637740","article-title":"Lidocaine treatment of neonatal convulsions, a therapeutic dilemma","volume":"36","author":"Wallin","year":"1988;","journal-title":"Eur J Clin Pharmacol"},{"issue":"(2);","key":"2020102715455368100_i1551-6776-17-1-31-b31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00609759","article-title":"The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates","volume":"13","author":"Mihaly","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"2020102715455368100_i1551-6776-17-1-31-b32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/088307380101601210","article-title":"Pervasive seizures caused by hypoxic-ischemic encephalopathy: treatment with intravenous paraldehyde","volume":"16","author":"Armstrong","year":"2001;","journal-title":"J Child Neurol"},{"issue":"24","key":"2020102715455368100_i1551-6776-17-1-31-b33","first-page":"3749","article-title":"The metabolism of paraldehyde to acetaldehyde in liver microsomes: evidence for the involvement of cytochrome P-450","volume":"32","author":"Zaleska","year":"1983;","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2020102715455368100_i1551-6776-17-1-31-b34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/adc.2007.134049","article-title":"Management of convulsive status epilepticus in children","volume":"94","author":"Yoong","year":"2009;","journal-title":"Arch Dis Child"},{"issue":"2","key":"2020102715455368100_i1551-6776-17-1-31-b35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0022-3476(84)81017-3","article-title":"Pharmacokinetics of paraldehyde disposition in the neonate","volume":"104","author":"Giacoia","year":"1984;","journal-title":"J Pediatr"},{"issue":"8","key":"2020102715455368100_i1551-6776-17-1-31-b36","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/adc.62.8.771","article-title":"Giving drugs per rectum for systemic effect","volume":"62","author":"Appleton","year":"1987;","journal-title":"Arch Dis Child"},{"issue":"11","key":"2020102715455368100_i1551-6776-17-1-31-b37","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/j.1528-1167.2009.02302.x","article-title":"Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy","volume":"50","author":"Filippi","year":"2009;","journal-title":"Epilepsia"},{"issue":"3","key":"2020102715455368100_i1551-6776-17-1-31-b38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1212\/WNL.38.3.467","article-title":"Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures","volume":"38","author":"Gal","year":"1988;","journal-title":"Neurology"},{"issue":"3","key":"2020102715455368100_i1551-6776-17-1-31-b39","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0387-7604(86)80082-1","article-title":"Valproic acid in neonatal status convulsivus","volume":"8","author":"Steinberg","year":"1986;","journal-title":"Brain Dev"},{"issue":"4","key":"2020102715455368100_i1551-6776-17-1-31-b40","first-page":"317","article-title":"Pharmacokinetic study of valproic acid in a neonate","volume":"2","author":"Irvine-Meek","year":"1982;","journal-title":"Pediatr Pharmacol"},{"issue":"12","key":"2020102715455368100_i1551-6776-17-1-31-b41","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/088307380001501216","article-title":"Intravenous valproate dosing in neonates","volume":"15","author":"Alfonso","year":"2000;","journal-title":"J Child Neurol"},{"issue":"6","key":"2020102715455368100_i1551-6776-17-1-31-b42","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2125.1996.00495.x","article-title":"Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures","volume":"42","author":"Vauzelle-Kervroedan","year":"1996;","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2020102715455368100_i1551-6776-17-1-31-b43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.1990.tb03772.x","article-title":"Pharmacokinetics of the individual enantiomers of vigabatrin (\u03b3-vinyl GABA) in epileptic children","volume":"30","author":"Rey","year":"1990;","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2020102715455368100_i1551-6776-17-1-31-b44","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","article-title":"Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations","volume":"45","author":"Bartelink","year":"2006;","journal-title":"Clin Pharmacokinetic"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/17\/1\/31\/1786849\/1551-6776-17_1_31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/17\/1\/31\/1786849\/1551-6776-17_1_31.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:40:20Z","timestamp":1738780820000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/17\/1\/article-p31.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-17.1.31","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,1]]}}}